Clinical Trial Update: Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sitravatinib plus tislelizumab in Esophageal Squamous Cell Carcinoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-06-13